198 related articles for article (PubMed ID: 19088261)
1. Tocilizumab for multirefractory adult-onset Still's disease.
De Bandt M; Saint-Marcoux B
Ann Rheum Dis; 2009 Jan; 68(1):153-4. PubMed ID: 19088261
[No Abstract] [Full Text] [Related]
2. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease.
Iwamoto M; Nara H; Hirata D; Minota S; Nishimoto N; Yoshizaki K
Arthritis Rheum; 2002 Dec; 46(12):3388-9. PubMed ID: 12483747
[No Abstract] [Full Text] [Related]
3. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature.
Perdan-Pirkmajer K; Praprotnik S; Tomšič M
Clin Rheumatol; 2010 Dec; 29(12):1465-7. PubMed ID: 20734215
[TBL] [Abstract][Full Text] [Related]
4. [Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease].
Sekkach Y; Elqatni M; Khattabi AE; Fatihi J; Hammi S; Badaoui M; Elomri N; Mekouar F; Amezyane T; Abouzahir A; Ghafir D
Presse Med; 2011; 40(7-8):e333-7. PubMed ID: 21550202
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade.
Rech J; Ronneberger M; Englbrecht M; Finzel S; Katzenbeisser J; Manger K; Manger B; Schett G
Ann Rheum Dis; 2011 Feb; 70(2):390-2. PubMed ID: 20650873
[No Abstract] [Full Text] [Related]
6. [Anti-IL-6 receptor antibody].
Nishimoto N
Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
[No Abstract] [Full Text] [Related]
7. Successful slow tocilizumab desensitization in a patient with adult onset Still disease.
Erdogan T; Yasar Bilge NS; Kasifoglu T
Biologicals; 2018 Sep; 55():17-18. PubMed ID: 30017556
[No Abstract] [Full Text] [Related]
8. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years.
Nakahara H; Mima T; Yoshio-Hoshino N; Matsushita M; Hashimoto J; Nishimoto N
Mod Rheumatol; 2009; 19(1):69-72. PubMed ID: 18762861
[TBL] [Abstract][Full Text] [Related]
9. [Successful tocilizumab therapy for adult onset Still's disease with intractable conditions over ten years].
Takahashi Y; Ochi H; Yanai A; Yamashita H; Itoh K; Mimori A
Nihon Naika Gakkai Zasshi; 2010 Jan; 99(1):130-2. PubMed ID: 20196484
[No Abstract] [Full Text] [Related]
10. Prolonged treatment with Tadekinig alfa in adult-onset Still's disease.
Kiltz U; Kiefer D; Braun J; Schiffrin EJ; Girard-Guyonvarc'h C; Gabay C
Ann Rheum Dis; 2020 Jan; 79(1):e10. PubMed ID: 30352887
[No Abstract] [Full Text] [Related]
11. Biological agents in the management of adult-onset Still's disease.
Girard-Guyonvarc'h C; Gabay C
Joint Bone Spine; 2019 Jan; 86(1):5-7. PubMed ID: 29631071
[No Abstract] [Full Text] [Related]
12. Anti-Golgi antibodies in adult Still's disease.
Staub HL; Souza F; Chan EK; von Mühlen CA
Clin Exp Rheumatol; 2003; 21(2):275-6. PubMed ID: 12747298
[No Abstract] [Full Text] [Related]
13. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.
Ortiz-Sanjuán F; Blanco R; Calvo-Rio V; Narvaez J; Rubio Romero E; Olivé A; Castañeda S; Gallego Flores A; Hernández MV; Mata C; Ros Vilamajo I; Sifuentes Giraldo WA; Caracuel MA; Freire M; Gómez Arango C; Llobet J; Manrique Arija S; Marras C; Moll-Tuduri C; Plasencia-Rodriguez C; Roselló R; Urruticoechea A; Velloso-Feijoo ML; Del Blanco J; González-Vela MC; Rueda-Gotor J; Pina T; Loricera J; González-Gay MA
Arthritis Rheumatol; 2014 Jun; 66(6):1659-65. PubMed ID: 24515813
[TBL] [Abstract][Full Text] [Related]
14. IL-1 Trap rilonacept in refractory adult onset Still's disease.
Petryna O; Cush JJ; Efthimiou P
Ann Rheum Dis; 2012 Dec; 71(12):2056-7. PubMed ID: 22679302
[No Abstract] [Full Text] [Related]
15. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD).
Yoshimura M; Makiyama J; Koga T; Miyashita T; Izumi Y; Torigoshi T; Motokawa S; Eguchi K; Migita K
Clin Exp Rheumatol; 2010; 28(1):141-2. PubMed ID: 20346255
[No Abstract] [Full Text] [Related]
16. Efficacy of tocilizumab in refractory adult-onset Still's disease; report of 2 cases.
Andrade-Ortega L; Irazoque-Palazuelos F; Muñoz-López S; Rosales-Don Pablo VM
Reumatol Clin; 2014; 10(3):199-200. PubMed ID: 24076178
[No Abstract] [Full Text] [Related]
17. Tocilizumab in refractory adult Still's disease.
Puéchal X; DeBandt M; Berthelot JM; Breban M; Dubost JJ; Fain O; Kahn JE; Lequen L; Longy-Boursier M; Perdriger A; Schaeverbeke T; Toussirot E; Sibilia J;
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):155-9. PubMed ID: 20740616
[TBL] [Abstract][Full Text] [Related]
18. [Tocilizumab effectiveness in adult Still's disease].
López Buitrago R; Estrada Dorronsoro S; Cervera Segura R; Espinosa Garriga G
Med Clin (Barc); 2012 Jan; 138(1):42-3. PubMed ID: 21605875
[No Abstract] [Full Text] [Related]
19. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome.
Kobayashi M; Takahashi Y; Yamashita H; Kaneko H; Mimori A
Mod Rheumatol; 2011 Feb; 21(1):92-6. PubMed ID: 20737186
[TBL] [Abstract][Full Text] [Related]
20. Two cases of adult-onset Still's disease treated with tocilizumab that achieved tocilizumab-free remission.
Kobayashi D; Ito S; Murasawa A; Narita I; Nakazono K
Intern Med; 2015; 54(20):2675-9. PubMed ID: 26466710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
